Market Overview

MissionIR News - RTI Biologics Launches New Biologic Implant, BioReady™ DBM Putty

Share:

New implant is for use in sports medicine, orthopedic, and spine surgeries

Atlanta, Georgia (PRWEB) October 28, 2012

MissionIR would like to highlight RTI Biologics, Inc., a leading publicly traded provider of sterile biologic implants around the world. The company is at the forefront of tissue-based innovations that repair and support the natural healing of human bone and tissues. RTI continues to break new ground with developments that are changing regenerative medicine. The company prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in spine, sports medicine, orthopedic, dental and other specialty surgeries.

In the company's news last week,

RTI Biologics announced the launch of an innovative, new biologic implant for use in sports medicine, orthopedic, and spine surgeries. BioReady™ DBM Putty and Putty with Chips is an instant use, 100 percent allograft DBM product. BioReady DBM putty is included in RTI's DBM portfolio, which already features BioSet™ DBM Paste and BioAdapt™ Foam.

BioReady DBM Putty is a ready-to-use demineralized bone matrix (DBM) implant that provides convenience, robust handling, verified osteoinductive* potential, and sterility. It was introduced at the RTI Biologics exhibit at the North American Spine Society (NASS) annual meeting in Dallas this week.

BioReady DBM Putty and Putty with Chips are 100 percent allograft, and each donor lot is tested for osteoinductive potential. Data shows that BioReady DBM Putty retains its osteoinductive potential throughout its entire shelf life. This ready-to-use implant does not require any preparation, such as thawing or mixing, and it is available in various sizes for use as a bone void filler in many types of surgical procedures.

“BioReady is an exciting allograft solution that complements our portfolio of DBM implants including BioSet and BioAdapt,” said Roger Rose, executive vice president and chief commercial officer for RTI Biologics. “This ready-to-use implant addresses a significant clinical need and ensures that we maximize every gift of donation received.”

All of RTI's implants go through a sterilization process validated by tissue type. The sterilization process used for BioReady DBM Putty is known as the Cancelle™ SP Demineralization Process. It uses a mixture of oxidative treatments and acid or alcohol washes to remove cellular debris and deactivate pathogens. Subsequent cleansing rinses serve to remove residual chemicals, maintaining biocompatibility.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb10065220.htm

View Comments and Join the Discussion!